← Back to Search

Other

Oral CT1812 for Age-Related Macular Degeneration

Phase 2
Recruiting
Research Sponsored by Cognition Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through week 104

Summary

This trial will test a new drug to treat dry age-related macular degeneration, assessing safety, effectiveness, and how well people tolerate it.

Who is the study for?
This trial is for people over 50 with a specific eye condition called Geographic Atrophy due to dry Age-Related Macular Degeneration. Participants must have decent vision and stable health conditions. Those with recent eye surgeries, other serious eye diseases, or allergies to study drugs can't join.
What is being tested?
The study tests the effectiveness of an oral drug named CT1812 against a placebo in improving this eye condition. It's a double-masked trial, meaning neither participants nor researchers know who gets the real drug or placebo during the 104-week study.
What are the potential side effects?
While not specified here, side effects may include typical reactions to oral medications such as stomach upset, headache, dizziness, or allergic reactions. The safety profile will be closely monitored throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through week 104
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through week 104 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye.
Secondary study objectives
Plasma concentration of CT1812
Safety and Tolerability of CT1812

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: CT1812 200 mgActive Control1 Intervention
Drug: CT1812 Active Study Drug
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Cognition TherapeuticsLead Sponsor
11 Previous Clinical Trials
1,033 Total Patients Enrolled
Anthony CaggianoStudy DirectorCognition Therapeutics Inc.

Media Library

CT1812 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05893537 — Phase 2
Age-Related Macular Degeneration Research Study Groups: Placebo, CT1812 200 mg
Age-Related Macular Degeneration Clinical Trial 2023: CT1812 Highlights & Side Effects. Trial Name: NCT05893537 — Phase 2
CT1812 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05893537 — Phase 2
~159 spots leftby Jul 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top